middle.news
Dimerix Secures US$10 Million Upfront from Everest Medicines for DMX-200 in Asia
9:13am on Thursday 20th of August, 2026 AEST
•
Biotechnology
Read Story
Dimerix Secures US$10 Million Upfront from Everest Medicines for DMX-200 in Asia
9:13am on Thursday 20th of August, 2026 AEST
Key Points
US$10 million upfront from Everest Medicines
Exclusive rights for DMX-200 in key Asian markets
Potential US$330 million in milestone payments
Five regional licenses total A$80 million upfront
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE